The shares are listed on the Nasdaq Global Market

Davis Polk advised the joint bookrunning managers in connection with a $250 million SEC-registered follow-on offering of 8,333,334 shares of common stock by RAPT Therapeutics, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “RAPT.”

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.

The Davis Polk corporate team included partner Emily Roberts and associate Sunny Xu. Partner David R. Bauer and associates Gabrielle Mazero and Elizabeth Pott provided intellectual property advice. Counsel Dustin Plotnick and associate Georgianna Eck provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post